 Connection
Adam Wolfe to Tumor Burden
This is a "connection" page, showing publications Adam Wolfe has written about Tumor Burden.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.023 |
|
|
|
-
Wolfe AR, Robb R, Hegazi A, Abushahin L, Yang L, Shyu DL, Trevino JG, Cruz-Monserrate Z, Jacob JR, Palanichamy K, Chakravarti A, Williams TM. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2021 01 15; 27(2):554-565.
Score: 0.714
-
Wolfe AR, Prabhakar D, Yildiz VO, Cloyd JM, Dillhoff M, Abushahin L, Alexandra Diaz D, Miller ED, Chen W, Frankel WL, Noonan A, Williams TM. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med. 2020 07; 9(13):4711-4723.
Score: 0.173
-
Wolfe AR, Trenton NJ, Debeb BG, Larson R, Ruffell B, Chu K, Hittelman W, Diehl M, Reuben JM, Ueno NT, Woodward WA. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget. 2016 Dec 13; 7(50):82482-82492.
Score: 0.137
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|